SCHEDULE: Vanguard Discloses 4.98% Stake in Cullinan Therapeutics
Schedule 13G Amendment
The Vanguard Group has filed an amended Schedule 13G, reporting a 4.98% beneficial ownership stake in Cullinan Therapeutics Inc. as of September 30, 2025.
Summary
- The Vanguard Group reported beneficial ownership of 2,943,325 shares of Cullinan Therapeutics Inc. common stock.
- This ownership represents 4.98% of the company's common stock outstanding.
- Vanguard holds sole dispositive power over 2,572,424 shares and shared dispositive power over 370,901 shares.
- Vanguard has shared voting power over 331,445 shares and no sole voting power.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cullinan Therapeutics Inc.
Sentiment
Score: 5
Explanation: The filing is a standard disclosure of beneficial ownership by a large institutional investor, providing factual information without expressing positive or negative sentiment about the issuer's performance or prospects.
Positives
- Vanguard's continued investment indicates a long-term, passive interest in Cullinan Therapeutics Inc.
- The stake is below the 5% threshold, reinforcing a passive investment strategy by Vanguard.
Negatives
- No specific negatives related to Cullinan Therapeutics Inc. are disclosed in this passive ownership filing.
Risks
- No specific risks related to Cullinan Therapeutics Inc. are disclosed in this filing, as it pertains to The Vanguard Group's ownership position.
Future Outlook
NA
Industry Context
The Vanguard Group is one of the world's largest investment management companies, primarily known for its passive investment strategies through index funds and ETFs. Their filing of a Schedule 13G indicates a significant, but passive, investment in Cullinan Therapeutics Inc., consistent with their broad market exposure approach.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake in the company.
- Company Management: Awareness of a large, passive institutional investor holding a substantial portion of the company's common stock.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date of event which requires filing of this statement (ownership snapshot date). |
| 2025-10-30 | Date of filing and signature by The Vanguard Group. |
Keywords
Cullinan Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.